Clinical Trials
7 trialsNCT00020774 2020-07-31
SCH 66336 With or Without Gemcitabine Followed by Surgery Compared With Surgery Alone in Treating Patients With Primary Liver Cancer
Jonsson Comprehensive Cancer Center
Phase 2 Withdrawn
NCT00038597 2018-10-30
Phase II Study of SCH66336, A Farnesyltransferase Inhibitor in Chronic Myelogenous Leukemia (CML)
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00038493 2018-10-29
Temozolomide and SCH66336 for Recurrent Glioblastoma Multiforme
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00773474 2016-02-18
Lonafarnib in Metastatic Breast Cancer
Hoosier Cancer Research Network
Phase 2 Terminated
NCT00081510 2015-04-15
Anastrozole Plus Lonafarnib (SCH 66336) or Plus Placebo for the Treatment of Advanced Breast Cancer (P03480)
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT00006351 2012-09-24
SCH 66336 Plus Gemcitabine in Treating Patients With Advanced Cancer of the Urinary Tract
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Completed
NCT00281515 2012-06-29
Comparison of Paclitaxel/Carboplatin and Lonafarnib to Paclitaxel/Carboplatin for First-line Treatment of Ovarian Cancer
AGO Study Group
Phase 2 Completed